Skip to main content

Eurobio Scientific launches a first rapid diagnostic test for the detection of the SARS CoV-2 virus antigen

Written by Customer Service on . Posted in Public Companies.

Eurobio Scientific launches a first rapid diagnostic test
for the detection of the SARS CoV-2 virus antigenParis, September 22,  2020 –6:00 pmEurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in vitro medical diagnostics and life sciences, today announces the launch of a first rapid diagnostic test for the detection of the SARS CoV-2 virus antigen . This test, Sofia® SARS Antigen developed by its American partner Quidel, is complementary to PCR tests which remain the performance gold standard in terms of detection of the virus responsible for COVID-19. It is already CE marked and immediately available for sale.As part of the current campaign to detect the presence of the SARS CoV-2 virus in patients, the number of tests performed in France has become of such magnitude (more than 1 million tests per week) that the delays in submitting results have lengthened considerably.
Even if their virus detection performance is lower than that of PCR tests, rapid antigenic tests make it possible to carry out a rapid initial screening of asymptomatic patients. Such a process would unclog testing laboratories while maintaining the scale of the viral activity monitoring campaign.With a catalog of products among the most complete on the market, with PCR tests, including its proprietary tests EBX 041 and FluCoSyn, as well as several serological tests, Eurobio Scientific is now completing its offer for the detection of SARS CoV-2, aware of the public health and economic stake that the current wave of the COVID-19 epidemic can represent.Immunofluorescence-based unit testFor many years, Eurobio Scientific has been ensuring the exclusive distribution in France of the Sofia® range from Quidel. This new unit test which allows the detection of the SARS-Cov-2 antigen completes this range which already includes, among others, the antigenic detection tests for Influenza A and B. It requires a nasal swab sample, and a Sofia® reader, which uses FIA (Fluorescence ImmunoAssay) technology to deliver a result in 15 minutes.These instruments are already widely available to Eurobio Scientific customers, with more than 350 readers mainly used for rapid diagnosis in hospitals across France.For Jean-Michel Carle, Chairman and CEO of Eurobio Scientific, “It was particularly important for our group to complete its range of screening tests in order to meet the demands of our customers. The overcrowding of analytical laboratories required an evolution in the testing technologies that we immediately make available to them. Our offer now includes a first test already CE marked and intended for our customers equipped with the Sofia® reader, mainly hospital departments requiring rapid unit tests. “Next financial meeting
Half-year 2020 financial results : October 15, 2020, after stock market closesAbout Eurobio Scientific  Attachment200922_EUROBIO_COVID-19_ANTIGENE_EN

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.